Jin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jin Zhang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Fengping Zhou
Department of Hematology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, P. R. China
4 shared publications- Baodong Ye
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
2 shared publications Hao Jiang
Department of Hematology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, P. R. China
2 shared publicationsShenhe Jin
Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China
2 shared publications- Wenjun Wu
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 shared publications Xiaochang Chen
Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P R China
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (43) , e51158
Bing-Neel syndrome successfully treated with venetoclax and zanubrutinib
Rationale: Bing-Neel syndrome (BNS) is an uncommon neurological manifestation of Waldenström’s Macroglobulinemia (WM). The diagnosis of BNS is still challenging due to its low incidence and high heterogeneity. A definite diagnosis relies on histopathology and cerebrospinal fluid (CSF) analysis to identify lymphoplasmacytic lymphocyte infiltration of the central nervous system. MYD88 L265P mutation also serves as a valuable diagnostic tool. To date, there is no consensus on the standard management of BNS, and current evidence is largely limited to reports on the use of high-dose chemotherapy and BTK inhibitors. Herein, we present a case of BNS who achieved remission following treatment with venetoclax and zanubrutinib. Furthermore, venetoclax was detected in CSF. Patient concern: A 66-year-old female with WM presenting with a headache. Diagnoses: Bing-Neel syndrome. Interventions: The patient was diagnosed with BNS through CSF examination and treated with zanubrutinib plus venetoclax. Outcomes: The patient’s symptoms resolved, and abnormal B lymphocytes were not detected in CSF. Lesson: BNS is an uncommon manifestation of WM, with significant diagnostic challenges. In the absence of standard management for BNS, high-dose chemotherapy and BTK inhibitors are widely used as front-line approaches. BCL-2 inhibitors, which have shown notable CNS-penetrating capacity, hold considerable promise for the treatment of BNS and merit further exploration.
- 23 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (43) , e51158
Open AccessBing-Neel syndrome successfully treated with venetoclax and zanubrutinib
Rationale: Bing-Neel syndrome (BNS) is an uncommon neurological manifestation of Waldenström’s Macroglobulinemia (WM). The diagnosis of BNS is still challenging due to its low incidence and high heterogeneity. A definite diagnosis relies on histopathology and cerebrospinal fluid (CSF) analysis to identify lymphoplasmacytic lymphocyte infiltration of the central nervous system. MYD88 L265P mutation also serves as a valuable diagnostic tool. To date, there is no consensus on the standard management of BNS, and current evidence is largely limited to reports on the use of high-dose chemotherapy and BTK inhibitors. Herein, we present a case of BNS who achieved remission following treatment with venetoclax and zanubrutinib. Furthermore, venetoclax was detected in CSF. Patient concern: A 66-year-old female with WM presenting with a headache. Diagnoses: Bing-Neel syndrome. Interventions: The patient was diagnosed with BNS through CSF examination and treated with zanubrutinib plus venetoclax. Outcomes: The patient’s symptoms resolved, and abnormal B lymphocytes were not detected in CSF. Lesson: BNS is an uncommon manifestation of WM, with significant diagnostic challenges. In the absence of standard management for BNS, high-dose chemotherapy and BTK inhibitors are widely used as front-line approaches. BCL-2 inhibitors, which have shown notable CNS-penetrating capacity, hold considerable promise for the treatment of BNS and merit further exploration.
- Open Access
- 19 February 2026
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 21 (1)
Prognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma
The prognostic role of Epstein-Barr virus (EBV) DNA in aggressive angioimmunoblastic T-cell lymphoma (AITL) remains unclear. This study aimed to investigat
- 19 February 2026
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 21 (1)
Open AccessPrognostic role of whole blood Epstein‑Barr virus DNA load in angioimmunoblastic T-cell lymphoma
The prognostic role of Epstein-Barr virus (EBV) DNA in aggressive angioimmunoblastic T-cell lymphoma (AITL) remains unclear. This study aimed to investigat
- Open Access
15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study
Background: Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective response rates (ORR) and potential as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in relapsed/refractory HR-MDS. We conducted a prospective multicenter trial to evaluate its efficacy and safety in previously untreated patients. Methods: This multicenter prospective study enrolled treatment-naïve HR-MDS patients (IPSS-R > 3.5). Venetoclax was administered on days 1–15 (escalated from 100 to 400 mg), combined with azacitidine (75 mg/m2) on days 1–7 of each 28-day cycle. The primary endpoint was ORR (2006 IWG criteria); secondary endpoints included complete remission (CR), overall survival (OS), and AML progression. Results: Twenty-eight patients (median age: 63 years) were enrolled, with a median follow-up of 8.5 months. ORR was 85.7% per 2006 IWG (CR: 35.7%, marrow CR: 50.0%), and 78.6% per 2023 IWG (CR: 35.7%). Responses were consistent across molecular and IPSS-R subgroups. Median OS was not reached. High neutrophil count and high cytogenetic risk were favorable factors; TP53 mutation/deletion was an adverse prognostic marker. Grade 3–4 hematologic toxicities included neutropenia (96.4%), anemia (71.4%), and thrombocytopenia (64.3%). Serious adverse events (35.7%) were mainly infections. No dose-limiting or unexpected toxicities were observed. Conclusions: The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-naïve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.
Open Access15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study
Background: Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective response rates (ORR) and potential as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in relapsed/refractory HR-MDS. We conducted a prospective multicenter trial to evaluate its efficacy and safety in previously untreated patients. Methods: This multicenter prospective study enrolled treatment-naïve HR-MDS patients (IPSS-R > 3.5). Venetoclax was administered on days 1–15 (escalated from 100 to 400 mg), combined with azacitidine (75 mg/m2) on days 1–7 of each 28-day cycle. The primary endpoint was ORR (2006 IWG criteria); secondary endpoints included complete remission (CR), overall survival (OS), and AML progression. Results: Twenty-eight patients (median age: 63 years) were enrolled, with a median follow-up of 8.5 months. ORR was 85.7% per 2006 IWG (CR: 35.7%, marrow CR: 50.0%), and 78.6% per 2023 IWG (CR: 35.7%). Responses were consistent across molecular and IPSS-R subgroups. Median OS was not reached. High neutrophil count and high cytogenetic risk were favorable factors; TP53 mutation/deletion was an adverse prognostic marker. Grade 3–4 hematologic toxicities included neutropenia (96.4%), anemia (71.4%), and thrombocytopenia (64.3%). Serious adverse events (35.7%) were mainly infections. No dose-limiting or unexpected toxicities were observed. Conclusions: The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-naïve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.
- Open Access
- 8 May 2024
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (11) , 4634-4659
Recent advances in engineering prodrug-based nanomedicines for cancer therapy
This review focuses on updates regarding a broad spectrum of fabrication advances and applications in the field of prodrug-based nanotechnologies in multiple cancer therapeutic strategies in response to the tumor microenvironment.
- 8 May 2024
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 5 (11) , 4634-4659
Open AccessRecent advances in engineering prodrug-based nanomedicines for cancer therapy
This review focuses on updates regarding a broad spectrum of fabrication advances and applications in the field of prodrug-based nanotechnologies in multiple cancer therapeutic strategies in response to the tumor microenvironment.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (8) , 2424-2430
CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy
Cofilin (CFL1) is one critical member of the actin deploy family (ADF). Overexpression of CFL1 is associated with aggressive features and poor prognosis in malignancies. We evaluated the expression of CFL1 in patients with chronic myeloid leukemia in the chronic phase (CML-CP), acute myelocytic leukemia (AML) and healthy controls. The role of CFL1 in imatinib therapy was also investigated using cell line. We found that the expression of CFL1 was lower in CML patients than that in healthy controls, and was significantly upregulated after imatinib therapy (p<0.05). CML patients with lower CFL1 achieved higher Major molecular response (MMR) rate after 6 months of imatinib therapy (p<0.05). Cofilin, P-cofilin and F-actin, especially branched F-actin were all upregulated after imatinib therapy. The lower CFL1 expression before treatment may predicts a better response to imatinib. Imatinib affects F-actin remodeling in CML patients by regulating CFL1 expression and activity.
- 1 January 2024
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 15 (8) , 2424-2430
Open AccessCFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy
Cofilin (CFL1) is one critical member of the actin deploy family (ADF). Overexpression of CFL1 is associated with aggressive features and poor prognosis in malignancies. We evaluated the expression of CFL1 in patients with chronic myeloid leukemia in the chronic phase (CML-CP), acute myelocytic leukemia (AML) and healthy controls. The role of CFL1 in imatinib therapy was also investigated using cell line. We found that the expression of CFL1 was lower in CML patients than that in healthy controls, and was significantly upregulated after imatinib therapy (p<0.05). CML patients with lower CFL1 achieved higher Major molecular response (MMR) rate after 6 months of imatinib therapy (p<0.05). Cofilin, P-cofilin and F-actin, especially branched F-actin were all upregulated after imatinib therapy. The lower CFL1 expression before treatment may predicts a better response to imatinib. Imatinib affects F-actin remodeling in CML patients by regulating CFL1 expression and activity.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 14
Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 14
Open AccessBispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
- Open Access
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1091782
TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an essential role in tumor initiation and progression. Therefore, immunotherapy, including immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) and chimeric antigen receptor T cell (CAR-T) therapy, has become a promising strategy for hematological malignancies. T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a novel checkpoint inhibitory receptor expressed on immune cells, including cytotoxic T cells, regulatory T cells, and NK cells. TIGIT participates in immune regulation via binding to its ligand CD155. Blockage of TIGIT has provided evidence of considerable efficacy in solid tumors in preclinical research and clinical trials, especially when combined with PD-1 inhibition. However, the mechanism and function of TIGIT in hematological malignancies have not been comprehensively studied. In this review, we focus on the role of TIGIT in hematological malignancies and discuss therapeutic strategies targeting TIGIT, which may provide a promising immunotherapy target for hematological malignancies.
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1091782
Open AccessTIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an essential role in tumor initiation and progression. Therefore, immunotherapy, including immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) and chimeric antigen receptor T cell (CAR-T) therapy, has become a promising strategy for hematological malignancies. T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a novel checkpoint inhibitory receptor expressed on immune cells, including cytotoxic T cells, regulatory T cells, and NK cells. TIGIT participates in immune regulation via binding to its ligand CD155. Blockage of TIGIT has provided evidence of considerable efficacy in solid tumors in preclinical research and clinical trials, especially when combined with PD-1 inhibition. However, the mechanism and function of TIGIT in hematological malignancies have not been comprehensively studied. In this review, we focus on the role of TIGIT in hematological malignancies and discuss therapeutic strategies targeting TIGIT, which may provide a promising immunotherapy target for hematological malignancies.
- Open Access
- 12 April 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 39 (6) , 2951-2959
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein
Phosphoinositide‑dependent kinase 1 (PDK1) is generally active in multiple myeloma (MM) and higher expression than other hematopoietic cells, which is associated with the drug resistance and the disease progression. Previous studies have demonstrated that PDK1 can be targeted therapeutically in MM. In the present study, we examined the combination effect of GSK2334470 (GSK‑470), a novel and highly specific inhibitor of PDK1, with proteasome inhibitor MG‑132 in MM cell lines. GSK‑470 monotherapy significantly inhibited growth of MM cell lines and induced apoptosis that was associated with the activation of both the intrinsic mitochondrial pathway and the extrinsic death receptor pathway. Moreover, GSK‑470 demonstrated synergistic growth inhibitory effects with MG‑132. Notably, treatment with these inhibitors resulted in an almost complete inhibition of phosphorylation of mammalian target of rapamycin on Ser2448 and Ser2481 and full activation of AKT. The combination therapy also caused an upregulation of PTEN and an increased nuclear accumulation of PTEN protein. Collectively, our results provide the rationale for novel combination treatment with PDK1 inhibitor and proteasome inhibitors to improve outcomes in patients with MM.
- 12 April 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 39 (6) , 2951-2959
Open AccessPDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein
Phosphoinositide‑dependent kinase 1 (PDK1) is generally active in multiple myeloma (MM) and higher expression than other hematopoietic cells, which is associated with the drug resistance and the disease progression. Previous studies have demonstrated that PDK1 can be targeted therapeutically in MM. In the present study, we examined the combination effect of GSK2334470 (GSK‑470), a novel and highly specific inhibitor of PDK1, with proteasome inhibitor MG‑132 in MM cell lines. GSK‑470 monotherapy significantly inhibited growth of MM cell lines and induced apoptosis that was associated with the activation of both the intrinsic mitochondrial pathway and the extrinsic death receptor pathway. Moreover, GSK‑470 demonstrated synergistic growth inhibitory effects with MG‑132. Notably, treatment with these inhibitors resulted in an almost complete inhibition of phosphorylation of mammalian target of rapamycin on Ser2448 and Ser2481 and full activation of AKT. The combination therapy also caused an upregulation of PTEN and an increased nuclear accumulation of PTEN protein. Collectively, our results provide the rationale for novel combination treatment with PDK1 inhibitor and proteasome inhibitors to improve outcomes in patients with MM.